



**Contacts:**

David Waldman or Justyna Gudaszevska  
Crescendo Communications Europe Sp. z.o.o  
Email: [mmd@crescendo-ir.com](mailto:mmd@crescendo-ir.com)  
Tel: (+48 71) 79 11 551

**Milestone Medical Inc. Ranked Third Most Popular  
NewConnect Listed Investment Choice of Polish Fund Managers**

LIVINGSTON, NJ, June 11, 2015 -- Milestone Medical Inc. (WAR: MMD), today announced that its shares were ranked the third most popular NewConnect listed investment by Polish fund managers. At the end of December 2014, the market value of Milestone Medical's shares held by investment funds amounted to approximately 8.2 million PLN (USD \$2.3 M). That constituted the third largest investment of asset managers managing mutual funds in NewConnect listed companies. The shares were allocated to the portfolios of four investment funds. The ranking was prepared by Analityz Online, one of the leading financial news agencies and providers of capital market research, based on the 2014 year-end financial statements of investment funds.

Leonard Osser, Chief Executive Officer of Milestone Medical, stated, "We appreciate the continued support and confidence in our business model that we have received from Polish fund managers. The capital raised enabled us to complete the process to receive CE Mark approval to sell and market our intra-articular and epidural instruments across the European Union and move forward with the clinical trials of our epidural instrument in the U.S. A major focus now is to finalize the regulatory approval process in the U.S for both instruments and commence the full commercial launch of our medical instruments in both Europe and the United States. We believe our plan to transition to the Main Market of the Warsaw Stock Exchange will help increase awareness and further expand the number of potential institutional investors in the company."

**About Milestone Medical Inc.**

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval for both instruments in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit [www.medicalmilestone.com](http://www.medicalmilestone.com).

**Safe Harbor Statement**

*This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*